Skip to main content
. 2018 Oct 1;11(10):4987–4995.

Table 2.

Baseline characteristics

Parameters TNBC patients (N=179)
Age (years) 45.9±6.1
BMI (kg/m2) 23.3±2.0
Obesity (n/%) 35 (19.6)
Smoke (n/%) 32 (17.9)
Hypertension (n/%) 41 (22.9)
Diabetes mellitus (n/%) 8 (4.5)
Dyslipidemia (n/%) 32 (17.9)
Hyperuricemia (n/%) 31 (17.3)
Chromic kidney disease (n/%) 4 (2.2)
Pathological grade (n/%)
    Grade 1 44 (24.6)
    Grade 2 117 (65.3)
    Grade 3 18 (10.1)
Tumor size (cm) 3.0 (2.2-4.0)
T stage (n/%)
    T1 34 (19.0)
    T2 135 (75.4)
    T3 10 (5.6)
N stage (n/%)
    N0 79 (44.1)
    N1 68 (38.0)
    N2 32 (17.9)
TNM stage (n/%)
    II 145 (81.0)
    III 34 (19.0)
ECOG performance (n/%)
    0 138 (77.1)
    1 41 (22.9)
LVEF (%) 67.0 (64.0-71.0)
cTnI (ng/mL) 0.021 (0.010-0.049)
NT-proBNP (ng/mL) 0.076 (0.060-0.096)

Data were presented as the mean ± standard deviation, count (%) or median (25th-75th quantiles). Obesity was defined as BMI ≥25 kg/m2. TNBC, triple-negative breast cancer; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; LVEF, left ventricular ejection fraction; cTnI, cardiac troponin I; NT-proBNP, N-terminal pro brain natriuretic peptide.